Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study.

By G. Albers, V. Bates, W. Clark, R. Bell, P. Verro, S. Hamilton. Journal of the American Medical Association (JAMA), 2000

759 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. (2007, background): “Causes of death were cerebral infarction (n=285), intracerebral haemorrhage (66), cerebral infarction or haemorrhage, unspecifi ed (50), myocardial infarction (34), pulmonary embolism ( 22 ), pneumonia (92), other vascular deaths (37), and other causes (88).”
Recommendations for the establishment of primary stroke centers (2000, methodology): “3%, with only 15% of treated patients having violations of treatment protocols.(25) These disparate results may support the need for regional stroke centers that have expertise and experience in treating patients with stroke and can closely follow detailed clinical protocols.”
Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage (2016, background): “Symptomatic intraparenchymal hemorrhage with mass effect occurs in approximately 2–7 % of patients with ischemic stroke who receive intravenous alteplase [325, 343–346].”
Protein therapeutics: a summary and pharmacological classification (2008, background): “Alteplase (recombinant tissue plasminogen activator (tPA; also known as PLAT)), is used to treat life-threatening blood clots in conditions such as coronary artery occlusion, acute ischaemic stroke and pulmonary embolis”